Czerwionka-Szaflarska M, Pawłowska M
Katedra i Klinika Gastroenterologii i Chorób Dzieci Akademii Medycznej w Bydgoszczy.
Pediatr Pol. 1996 Jul;71(7):599-604.
The aim of the study was to determine the effectiveness of Uro-Vaxom in the treatment in children with recurrent urinary tract infections induced by E. coli. Our investigations confirmed that in the group of children receiving pharmacotherapy and Uro-Vaxom, a significant increase of sIgA in the urine was found, lasting for at least 3 months. During this period no infection appeared in 92% of the examined children. The authors recommend including Uro-Vaxom in the therapy of children, because it is effective and well-tolerated by children.
该研究的目的是确定Uro-Vaxom在治疗由大肠杆菌引起的复发性尿路感染儿童中的有效性。我们的调查证实，在接受药物治疗和Uro-Vaxom的儿童组中，尿液中的分泌型免疫球蛋白A（sIgA）显著增加，持续至少3个月。在此期间，92%的受检儿童未出现感染。作者建议将Uro-Vaxom纳入儿童治疗方案，因为它有效且儿童耐受性良好。
